ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $7.13B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 15.77M
Average 16.40M
IBRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ImmunityBio, Inc.NASDAQ: IBRX
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $184.57M (cash outflow) rose 174.3% year over year, behind the +218.3% change in trailing-twelve-month net income. Sequentially, it fell 19.9% from the prior quarter. Over 3 fiscal years it compounded at -5.5% a year.
Context
- Net income amounted to 310.2% of revenue in FY2025, down 2495.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$1.04B (+196.4%) for the fiscal year ending Dec 2026, a step up from the -15.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$184.57M-19.9% QoQ
- Last fiscal yearDec 2025
- -$351.47M-15.0% YoY
- LTMSep 2026
- -$1.11B+218.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +174.3% | +122.6% | -51.7 pp |
| 1 year | -15.0% | +196.4% | +211.4 pp |
| 3-year CAGR | -5.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (351.47M) USD
- Year-over-year change
- +15.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (351.47M) | +15.0% |
| FY2024 | 2024-12-31 | (413.65M) | +29.2% |
| FY2023 | 2023-12-31 | (583.85M) | -40.2% |
| FY2022 | 2022-12-31 | (416.57M) | -20.1% |
| FY2021 | 2021-12-31 | (346.79M) | — |
Net Income vs competitors
How IBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +218.3% is the 3rd highest of 11, against a peer median of -16.9%.
- Net income amounts to 607.8% of revenue for IBRX, versus a peer median of 61.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.79B USD | -10.5% | — | 110.5% | |
| LTM Jun 2026 | €1.71B EUR | +348.2% | — | 64.7% | |
| LTM Sep 2026 | $1.11B USD | +218.3% | -5.5% | 607.8% | |
| LTM Mar 2026 | $442.72M USD | -23.4% | — | 676.0% | |
| LTM Sep 2026 | $220.54M USD | -44.5% | -0.4% | 58.2% | |
| LTM Mar 2026 | €217.14M EUR | +906.0% | — | 582.2% | |
| LTM Mar 2026 | $173.76M USD | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $99.93M USD | -10.2% | -2.9% | — | |
| LTM Mar 2026 | $27.59M USD | +28.8% | -20.5% | 7.2% | |
| LTM Mar 2026 | $9.47M USD | -39.5% | — | 40.9% | |
| LTM Sep 2026 | $2.81M USD | -98.7% | -12.6% | 0.2% | |
| Peer median (excluding IBRX) | — | -16.9% | -12.6% | 61.5% | |
Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (346.79M) | (416.57M) | (583.85M) | (413.65M) | (351.47M) |
| Depreciation & Amortization | 14.24M | 18.26M | 18.51M | 17.55M | 15.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 57.18M | 40.18M | 49.16M | 34.43M | 36.81M |
| Change in Working Capital | (15.4M) | (16M) | 3.83M | (19.42M) | (54.33M) |
| Accounts Receivables | 0 | 0 | 0 | (2.36M) | (40.21M) |
| Inventory | 0 | 0 | 0 | (8.27M) | (6.33M) |
| Accounts Payables | 0 | 0 | (6.48M) | (3.17M) | (190K) |
| Other Working Capital | (15.4M) | (16M) | 10.3M | (5.62M) | (7.6M) |
| Other Non-Cash Items | 16.35M | 36.62M | 145.44M | (10.16M) | 48.53M |
| Operating Cash Flow | (274.42M) | (337.51M) | (366.76M) | (391.24M) | (304.94M) |
| Capital Expenditures | (33.56M) | (78.16M) | (30.58M) | (6.89M) | (3.85M) |
| Acquisitions (Net) | 0 | 0 | 0 | (1M) | 0 |
| Purchases of Investments | 0 | 0 | (10.36M) | (140.22M) | (241.37M) |
| Sales of Investments | 0 | 0 | 10.47M | 136.61M | 95.82M |
| Other Investing Activities | (51.32M) | 105.46M | 0 | (747K) | 0 |
| Investing Cash Flow | (84.89M) | 27.3M | (30.47M) | (12.25M) | (149.8M) |
| Debt Repayment | 338.5M | 174.07M | 451.39M | 96.89M | 1.72M |
| Common Stock Issued | 0 | 0 | 110.4M | 111.36M | 400.78M |
| Common Stock Repurchased | (4.06M) | (616K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 171.01M | 60.16M | (3.44M) | 73.38M | (2.27M) |
| Financing Cash Flow | 505.44M | 233.61M | 558.34M | 281.63M | 400.24M |
| Effect of Forex Changes | 48K | 284K | (292K) | (23K) | 15K |
| Net Change in Cash | 146.19M | (76.32M) | 160.82M | (121.88M) | (54.48M) |
| Free Cash Flow | (307.98M) | (415.67M) | (397.34M) | (398.12M) | (308.78M) |
ImmunityBio, Inc.
NASDAQ:IBRX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.